Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KPTI Karyopharm Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: KPTI
Price (delayed)
$4.33
Market cap
$37.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.17
Enterprise value
$184.99M
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related
Highlights
The net income has soared by 57% YoY and by 18% from the previous quarter
The EPS has soared by 57% YoY and by 14% from the previous quarter
KPTI's debt is up by 6% YoY but it is down by 4% from the previous quarter
Karyopharm Therapeutics's quick ratio has plunged by 58% YoY and by 23% from the previous quarter
The equity has contracted by 22% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of KPTI
Market
Valuations
Earnings
Shares outstanding
8.64M
Market cap
$37.41M
Enterprise value
$184.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.3
Revenue
$142.13M
Gross profit
$136.73M
Operating income
-$118.94M
Net income
-$62.52M
EBIT
-$19.97M
EBITDA
-$19.64M
Free cash flow
-$122.69M
Per share
Balance sheet
Liquidity
EPS
-$8.17
EPS diluted
-$13.27
Free cash flow per share
-$14.49
Book value per share
-$24.46
Revenue per share
$16.78
TBVPS
$15.08
Total assets
$127.71M
Total liabilities
$333.6M
Debt
$186.7M
Equity
-$205.88M
Working capital
$29.87M
Debt to equity
-0.91
Current ratio
1.33
Quick ratio
1.17
Net debt/EBITDA
-7.52
Margins
Efficiency
Dividend
EBITDA margin
-13.8%
Gross margin
96.2%
Net margin
-44%
Operating margin
-83.7%
Return on assets
-36%
Return on equity
N/A
Return on invested capital
-8.8%
Return on capital employed
-53.5%
Return on sales
-14%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KPTI stock price
How has the Karyopharm Therapeutics stock price performed over time
Intraday
-1.14%
1 week
-4.63%
1 month
-5.66%
1 year
-70.4%
YTD
-57.3%
QTD
15.78%
Financial performance
How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$142.13M
Gross profit
$136.73M
Operating income
-$118.94M
Net income
-$62.52M
Gross margin
96.2%
Net margin
-44%
KPTI's net margin has soared by 58% YoY and by 16% from the previous quarter
The net income has soared by 57% YoY and by 18% from the previous quarter
KPTI's operating margin is up by 11% YoY
KPTI's operating income is up by 10% YoY
Price vs fundamentals
How does KPTI's price correlate with its fundamentals
Growth
What is Karyopharm Therapeutics's growth rate over time
Valuation
What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.3
The EPS has soared by 57% YoY and by 14% from the previous quarter
The equity has contracted by 22% YoY and by 11% from the previous quarter
The P/S is 93% lower than the 5-year quarterly average of 3.8 and 57% lower than the last 4 quarters average of 0.6
The revenue has contracted by 2.1% from the previous quarter
Efficiency
How efficient is Karyopharm Therapeutics business performance
The ROS has soared by 84% YoY and by 48% from the previous quarter
Karyopharm Therapeutics's return on invested capital has surged by 77% YoY and by 43% QoQ
KPTI's ROA is up by 38% YoY and by 9% QoQ
Dividends
What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KPTI.
Financial health
How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 62% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has plunged by 58% YoY and by 23% from the previous quarter
The current ratio has plunged by 56% YoY and by 22% from the previous quarter
KPTI's debt is 191% more than its equity
The equity has contracted by 22% YoY and by 11% from the previous quarter
KPTI's debt to equity is up by 13% since the previous quarter and by 13% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.